JPRN-C000000232已完成未知
A randomized, parallel-group, multicenter clinical trial to evaluate the preventive effect on acute exacerbation of chronic obstructive pulmonary disease (COPD) with Carbocisteine (1500mg/day) - Preventive effect on acute exacerbation of chronic obstructive pulmonary disease with Carbocisteine (PEACE Study)
Department of Respiratory Medicine Juntendo University, School of Medicine0 个研究点目标入组 150 人开始时间: 2006年12月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 40years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Intolerance for Carbocisteine 2. Use of mucolytic agents within one month prior to beginning of the study 3. Use of antibiotics at the beginning of the study 4. Bronchiectasis, pneumonia, interstitial lung disease, tuberculosis 5. Carcinoma 6. Previous lung transplant or lung volume reduction surgery 7. Pregnant or breastfeeding 8. Attendance in the other study within 3 months prior to the beginning of the study 9. Underlying severe disease
研究者
相似试验
进行中（未招募）
不适用
A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd) versus placebo in patients with type 2 diabetes and moderate or severe renal insufficiencyEUCTR2007-003723-21-DEovartis Pharma Services AG525
进行中（未招募）
不适用
A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd or 100 mg qd) versus placebo in patients with type 2 diabetes and moderate renal insufficiency - NDEUCTR2007-003723-21-ITOVARTIS FARMA300
进行中（未招募）
不适用
A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd or 100 mg qd) versus placebo in patients with type 2 diabetes and moderate renal insufficiencyDiabetes Type 2MedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2007-003723-21-FIovartis Pharma Services AG300
进行中（未招募）
不适用
A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd) versus placebo in patients with type 2 diabetes and moderate or severe renal insufficiencyDiabetes Type 2EUCTR2007-003723-21-SEovartis Pharma Services AG525
进行中（未招募）
不适用
A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd or 100 mg qd) versus placebo in patients with type 2 diabetes and moderate renal insufficiencyEUCTR2007-003723-21-FRovartis Pharma Services AG300